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Abstract EMSY links the BRCA2 pathway to sporadic
breast/ovarian cancer. It encodes a nuclear protein that
binds to the BRCA2 N-terminal domain implicated in
chromatin/transcription regulation, but when sporadically
amplified/overexpressed, increased EMSY level represses
BRCA2 transactivation potential and induces chromosomal
instability, mimicking the activity of BRCA2 mutations in
the development of hereditary breast/ovarian cancer. In
addition to chromatin/transcription regulation, EMSY may
also play a role in the DNA-damage response, suggested by
its ability to localize at chromatin sites of DNA damage/
repair. This implies that EMSY overexpression may also
repress BRCA2 in DNA-damage replication/checkpoint
and recombination/repair, coordinated processes that also
require its interacting proteins: PALB2, the partner and
localizer of BRCA2; RPA, replication/checkpoint protein
A; and RAD51, the inseparable recombination/repair
enzyme. Here, using a well-characterized recombination/
repair assay system, we demonstrate that a slight increase
in EMSY level can indeed repress these two processes
independently of transcriptional interference/repression.
Since EMSY, RPA and PALB2 all bind to the same
BRCA2 region, these findings further support a scenario
wherein: (a) EMSY amplification may mimic BRCA2
deficiency, at least by overriding RPA and PALB2, crip-
pling the BRCA2/RAD51 complex at DNA-damage and
replication/transcription sites; and (b) BRCA2/RAD51 may
coordinate these processes by employing at least EMSY,
PALB2 and RPA. We extensively discuss the molecular
details of how this can happen to ascertain its implications
for a novel recombination mechanism apparently con-
ceived as checkpoint rather than a DNA repair system for
cell division, survival, death, and human diseases, includ-
ing the tissue specificity of cancer predisposition, which
may renew our thinking about targeted therapy and
prevention.
Keywords Tumor-suppressor genes  Oncogenes 
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Introduction
EMSY amplification in sporadic breast and ovarian cancer
mimics the activity of BRCA2 mutations in the development
of this disease’s hereditary form (Hughes-Davies et al.
2003). EMSY encodes a large nuclear protein that binds to
the BRCA2 N-terminal domain encoded by exon 3 of the
BRCA2 gene (BRCA2ex3). Adjacent to the EMSY N-ter-
minal domain that interacts with BRCA2ex3 reside con-
served residues that specifically bind chromatin-remodeling
HP1b and BS69 proteins, implicating EMSY in chromatin
regulation. Whereas BRCA2ex3 possesses intrinsic histone
acetyltransferase (HAT) activity, chromatin-relaxation
activity required for transcription, replication and recombi-
nation/repair, HP1b binds to methylated histones involved
in chromatin assembly that usually impedes these processes.
A role for EMSY in chromatin regulation is also suggested
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by the findings that overexpression of a truncated form of
EMSY represses the transactivation potential of BRCA2ex3
and induces chromosomal instability (CIN), implicating
BRCA2 in the development of non-familial cancer as well
(Hughes-Davies et al. 2003; Raouf et al. 2005).
However, BRCA2ex3 may also be directly involved in
the maintenance of chromosomal stability through its
interaction with RPA, single-strand DNA (ssDNA)-binding
replication protein A, and PALB2, two proteins required
for development of the DNA-damage response (DDR),
including BRCA2/RAD51-mediated homologous recom-
bination (HR) repair of DNA double-strand breaks (DSBs)
(Wong et al. 2003; Xia et al. 2006), a well-established
function of BRCA2 (Thorslund and West 2007; Moynahan
and Jasin 2010). Generally, DSBs, such as those generated
by mega-endonucleases (i.e., I-SceI), ionizing radiation
(IR), DNA cross-linking agents or by overexpressing
oncogenes, activate the DDR orchestrated by PIKKs, the
serine/threonine PI3K-like kinases ATM, ATR and DNA-
PK, which, once recruited/localized at sites of such lethal
damage, trigger a cascade of phosphorylation events in
several downstream target proteins that coordinate DNA-
damage checkpoints (i.e., cell-cycle arrest) with recombi-
nation/repair or activate p53-dependent or -independent
apoptosis/senescence (Shiloh 2003; Kastan and Bartek
2004; Harper and Elledge 2007; Branzei and Foiani 2008;
Halazonetis et al. 2008).
Briefly, while PALB2 links BRCA2 to BRCA1, which
localizes PALB2/BRCA2/RAD51 complex at chromatin
and I-SceI/IR-induced DSBs (Xia et al. 2006; Zhang et al.
2009), RPA coats ssDNA and recruits ATR through its
interacting protein ATRIP, after the localization of acti-
vated ATM and the processing of DSB ends into ssDNA
by BRCA1 and MRE11/RAD50/NBS1 (MRN) complex
(Kastan and Bartek 2004; Jazayeri et al. 2006). In addition,
through its interaction with MRN, RPA also recruits ATR/
ATRIP to ssDNA tracts at stalled forks, generated spon-
taneously or induced by ultraviolet (UV) light, hydroxy-
urea (HU) or methyl methane sulfonate (MMS) (Harper
and Elledge 2007; Olson et al. 2007). MRN is the DNA-
binding/bridging/unwinding/exonuclease component of
BRCA1-associated genome surveillance complex (BASC)
that also contains BARD1 (BRCA1-associated ring
domain), ATM, ATR, the DNA-helicase BLM, and repli-
cation factors that load DNA-polymerase processivity
factor proliferating cell nuclear antigen (PCNA) on the
forks (Wang et al. 2000; Greenberg et al. 2006). BRCA1/
MRN not only localizes ATM, ATR and BRCA2/RAD51
complexes at sites of DNA damage, but also facilitates the
ability of ATR and ATM to interact with and phosphory-
late several downstream targets, most notably, their prox-
imal effector checkpoint-kinases CHK1 and CHK2,
respectively, and the cohesin subunit SMC1 (structural
maintenance of chromosome 1). Whereas CHK1 and
CHK2 target the cyclin-dependent kinases CDK1 and
CDK2 for inactivation, thereby imposing G1/S and G2/M
checkpoints, SMC1 enhances sister chromatid (SC) cohe-
sion (SCC) to keep them perfectly aligned for BRCA2/
RAD51-mediated HR, thus ensuring error-free repair of
DNA damage, replication-fork progression and SC segre-
gation, thereby maintaining chromosomal stability in both
structure and number (Shiloh 2003; Kastan and Bartek
2004; Branzei and Foiani 2008; Moynahan and Jasin
2010).
In addition to RPA and PALB2, evidence indicates that
BRCA2 may also employ EMSY in DDR development.
(a) The inherited, cancer-eliciting BRCA2ex3 mutations
that inactivate its transactivation potential and block its
binding to EMSY (Hughes-Davies et al. 2003) also abro-
gate its interaction with RPA (Wong et al. 2003) and
PALB2 (Xia et al. 2006); (b) EMSY localizes to IR-
induced DNA damage/repair foci (Hughes-Davies et al.
2003) in a manner similar to BRCA2 co-localizing with
BRCA1, BARD1, MRN, RPA, RAD51 and ATR at UV-
stalled forks, marked by PCNA (Scully and Livingston
2000); (c) EMSY-interacting HP1b protein binds to CAF-
1, the histone chaperone chromatin-assembly factor that
interacts with PCNA (Groth et al. 2007), and like BRCA2,
CAF-1 also stabilizes replication forks; in its absence,
stalled forks can collapse into DSBs (Lomonosov et al.
2003; Ye et al. 2003). CAF-1/PCNA ensures the loading of
acetylated histones behind replication forks (Groth et al.
2007), whereas BRCA2 may use EMSY/HP1b to provide
such histones by displacing nucleosomes ahead of such
forks, allowing fork movement and RPA coating of nascent
ssDNA and recruiting/activating ATR; and (d) overexpres-
sion of a truncated form of EMSY in human mammary
epithelial cells induces SC-type abnormalities displayed
by BRCA2-deficient cells (Raouf et al. 2005). Collectively,
these findings raise the hypothesis that increased EMSY
level may mimic BRCA2 deficiency in CIN, at least by
overriding RPA and PALB2.
To gain insights into this scenario, we increased EMSY
level in sporadic breast cancer MCF-7 cells and determined
whether it induces other phenotypes of BRCA2 deficiency.
In addition to SC-type abnormalities [quadri-radial chro-
mosomes, breakage, tri-radial chromosomes, chromosome
loss/gain (aneuploidy/polyploidy), deletions, amplifications,
inversions, and translocations], BRCA2-deficient cells also
exhibit (a) a deficit in HR repair of I-SceI-induced DSBs;
(b) normal efficiency of DSB repair by the error-prone, non-
homologous end joining (NHEJ) pathway; (c) heightened
efficiency of DSB repair by ssDNA annealing (SSA), a
RAD51-independent gene deletion process restricted to
DSBs generated between direct repeats; (d) hypersensitivity
to MMS, HU, UV, IR and chemotherapeutic, DSB-inducing
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agents; (e) defective G2/M checkpoint; (f) an amplified rate
of both gene mutations and reversions; (g) a hyper-recom-
bination phenotype, characterized by an increased rate of
spontaneous HR, gene conversion, inversion and deletion/
amplification (crossover) events; and last but not least (h) an
augmented rate of spontaneous SC replication slippage
(SCRS), a RAD51-independent gene deletion/amplification
process (Scully and Livingston 2000; Venkitaraman 2002;
Abaji et al. 2005; Gudmundsdottir and Ashworth 2006;
Moynahan and Jasin 2010). These phenotypes are also
characteristic features of BRCA1-deficient cells, except that
they exhibit a deficit in DSB repair by SSA (Scully and
Livingston 2000; Venkitaraman 2002; Cousineau et al.
2005; Gudmundsdottir and Ashworth 2006; Moynahan and
Jasin 2010).
These findings indicate that EMSY-overexpressing
MCF-7 cells only partially mimic BRCA-deficient tumor
cells. They exhibit both an enhanced rate of SCRS and
decreased efficiency of HR repair of I-SceI-induced DSBs,
but show a decreased rate of spontaneous HR and normal
efficiency of DSB repair by SSA, suggesting that increased
EMSY level interferes with the recruitment/activation of
ATR without affecting that of ATM or the processing
of DSB ends into ssDNA by BRCA1/MRN or the ability of
BRCA2/RAD51 to bind/stabilize ssDNA. We extensively
discuss the molecular details of how this can happen, to
appreciate all phenotypes of BRCA deficiency as markers
of deregulated HR orchestrating at least S/G2/M-transition
checkpoints and gene mutation-avoidance systems.
Materials and methods
DNA manipulations, cell lines, culture,
and DNA transfections
Three distinct recombination/repair reporter MCF-7 cell
lines were transfected with pcDNA3.1Neo-based expres-
sion vector, with or without short EMSY (1–478) (Hughes-
Davies et al. 2003), using FuGENE 6 transfection reagent
(Boehringer-Mannheim, Indianapolis, IN). Forty-eight
hours later, the transfected cells were cultured in medium
containing G418 (600 lg/mL). Independent G418R cell
clones were picked and amplified individually to analyze
short EMSY integration and its expression by PCR, RT-
PCR and Western blotting.
PCR
Genomic DNA was extracted from individual cell clones,
and 400 ng subjected to PCR with the following primer pair:
EMSY37-F (50-agggatgaatgcaaaagaat-30) and pcDNA3.1-
Neo-R (50-tctgagatgagtttttgttc-30), which specifically
amplifies a fragment of 1,397 bp from exogenous EMSY but
not endogenous EMSY.
RT-PCR
RNA was extracted from individual cell clones with Trizol
reagent and transcribed to cDNA with reverse transcriptase
and primers (hexamers) from the SuperScript First-Strand
Synthesis System RT-PCR kit (Invitrogen, Carlsbad, CA).
The same primer pair described for PCR was employed to
amplify exogenous EMSY cDNA. In the same reaction tube,
EMSY1810-R (50-ttttctcctccagcatttag-30) was added to
amplify, together with EMSY37-F, a 1,773-bp fragment from
endogenous wild-type (wt) EMSY. In reaction controls, the
primer pair 18s-F (50-tgaggccatgattaagaggg-30) and 18s-R
(50-cgctgagccagttcagt gtag-30) amplified a 642-bp fragment
of ribosomal RNA. PuroR, HygR, and BRCA2 expression
was assessed with Puro-F (50-cgaccttccatgaccgagta-30) and
Puro-R (50-gccttccatctgttgctg-30), Hyg-F (50-cggcgagtacttct
acacagc-30) and Hyg-R (50-ttcgaacacgcagatgcagtcg-30),
BRCA2-F (50-ccaagtcatgccacacattc-30) and BRCA2-R
(50-ttgaccaggtgcggtaaaat-30). In addition, RAD51 expression
was analyzed with the primer pair RAD51-F (50-gagtaatg
gcaatgcagatgca-30) and RAD51-R (50tcgacccgagtagtctgt
tct-30). PCR amplifications were undertaken with the Expand
High Fidelity PCR System kit (Boehringer-Mannheim).
Protein manipulations
Proteins were extracted and quantified as described previ-
ously (Abaji et al. 2005). Fifty micrograms of protein
extract was separated on 8% sodium dodecyl sulfate-
polyacrylamide gel, transferred to nitrocellulose mem-
branes (Amersham, Piscataway, NJ) and probed with crude
rabbit antisera (1/3,000) directed against EMSY. For
RAD51 detection, 50 lg of protein extracts was separated
on 12.5% gel and probed with mouse anti-RAD51 antibody
(51RAD01, Calbiochem, La Jolla, CA) with actin as
loading control (ACTN05, Medicorp, Montreal, QC,
Canada).
HR frequency and rate
HR rate and frequency were determined from at least two to
three independent experiments, respectively, as described
previously (Lemelin et al. 2005). Briefly, in each experi-
ment and for each cell line, 12 independent cultures (1–100
cells) were plated in parallel and cultured to confluence.
Cells were trypsinized, counted, and a portion was taken for
plating efficiency estimation. 5 9 105 cells were plated
24 h before adding Puro at 1.0 lg/mL. Since HR between
direct repeats can delete HygR during culture, direct-repeat
cell lines were maintained without hygromycin before Puro
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selection. The number of PuroR colonies divided by the
number of plated cells determined HR frequency. The HR
rate was calculated from these frequencies by the fluctua-
tion test.
For I-SceI-induced HR experiments, the vectors pbac-
tinSceI and pFRED25, which express the meganuclease
I-SceI and green fluorescent protein (GFP), respectively,
were co-transfected into 2 9 105 cells with FuGENE 6. In
parallel experiments, the same number of cells was trans-
fected with pFRED25 and pMC1Neo, the latter to correct
for DNA content as a control for I-SceI efficiency. GFP-
expressing cells were counted 48 h after transfection to
examine the efficiency of transfection and normalize HR
frequencies. Puro selection was performed 10 days after
transfection. The frequency of I-SceI-induced HR was
calculated by dividing the number of PuroR colonies
transfected with I-SceI by the number of PuroR colonies
transfected with control DNA and normalized for trans-
fection efficiency.
Statistical analysis
HR frequencies and rates were assessed by one-way
ANOVA. For the analysis of recombination/repair path-




The MCF-7 cell lines employed as backgrounds for EMSY
overexpression each carries a single, intact copy of a
recombination/repair construct containing either a direct-
repeat or an inverted-repeat of two inactive PuroR genes
separated by the HygR gene (Fig. 1; Lemelin et al. 2005).
Deleting EagI and BssHII restriction sites and inserting one
I-SceI cleavage site inactivated the full-length Puro gene,
whereas the wt Puro gene contained an inactivating 50
deletion, including the promoter. A recombination/repair
event between the two Puro cassettes would reconstitute a
functional PuroR gene through loss of I-SceI and gain of wt
EagI/BssHII sites, restoring resistance to the drug puro-
mycin in colony assay.
In this type of assay system (Moynahan and Jasin 2010),
the efficiency of recombination/repair also depends on the
ability of a cell to at least survive the damage and express the
reporter gene. It has been consistently demonstrated with
various organisms that when more than two copies of a
reporter gene lie adjacent to one another, the tandem can
undergo chromatin assembly and transcription repression,
an epigenetic phenomenon known as homology- or repeat-




























Fig. 1 Homologous recombination (HR) between direct and inverted
repeats. HR reconstitutes a functional PuroR gene through loss of the
I-SceI site and gain of EagI/BssHII sites. Since I-SceI insertion mutation
in ScePuro entails the deletion of EagI and BssHII sites, only error-free
HR repair events between the two PuroR cassettes can restore a
functional Puro gene. Gene conversion restores one functional Puro
gene without affecting the overall structure of the locus, whereas
crossover associated or not with gene conversion inverts HygR gene
between inverted Puro repeats (a) or deletes HygR between direct Puro
repeats (b). Deletion events can also result from SCRS or SSA (see text)
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position-effect variegation, in which chromatin assembly
can spread into adjacent domains (Henikoff 1998). The use
of single-copy MCF-7 cell clones would thus prevent
repression of PuroR gene by HIGS. In addition, the PuroR
gene was also designed to escape repression from the adja-
cent marker HygR gene (Lemelin et al. 2005). It has also
been consistently shown in various organisms that in such
cell clones, which had initially been selected for the
expression of a marker gene, the adjacent reporter gene
was usually repressed (Villemure et al. 2001; Eszterhas
et al. 2002). Such an HIGS-independent, gene-silencing
phenomenon, termed ‘transcriptional interference’ and
‘promoter suppression’, can occur whether adjacent tran-
scription units are arranged in direct or inverted orientations.
Transcriptional interference/suppression is cis-acting, epi-
genetic and heritable. Since EMSY interacts with CAFs and
its increased level represses the transcription of reporter
genes (Hughes-Davies et al. 2003), a transcription inter-
ference/suppression-free assay system was considered
necessary for this study.
Nevertheless, we investigated the effect of increased
EMSY level on the expression of HygR and PuroR genes at
distinct loci. HygR expression is driven by the Herpes
simplex virus thymidine kinase (TK) gene promoter,
whereas that of PuroR is under control of the strong cel-
lular-housekeeping phosphoglycerate kinase gene promoter
(Lemelin et al. 2005). MCF-7 cells exhibit normal EMSY
copy number and expression level, whereas overexpression
of a truncated EMSY form, containing the binding sites of
BRCA2, HP1b and BS69, represses both BRCA2ex3-
transactivation potential and expression of a TK gene
promoter in transient assays (Hughes-Davies et al. 2003).
To examine this in stable MCF-7 cell clones, the three
distinct reporter cell lines dA9, iA12 and iA7, grown in
Hyg-free medium, were transfected with pcDNA3.1Neo
containing or not short EMSY (Hughes-Davies et al. 2003).
Since DNA transfection per se can activate DDR (Igou-
cheva et al. 2006) and DDR activation can repress both
p53-dependent and -independent gene expression (Zhou
et al. 2007), and p53 can repress all viral promoters driving
the expression of reporter genes (Lemelin et al. 2005),
independent NeoR cell clones were picked, amplified and
only then analyzed by PCR of genomic DNA, RT-PCR and
Western blotting. Direct-repeat (dA9) and inverted-repeat
(iA12 and iA7) cell lines presented similar expression
levels of either endogenous or exogenous EMSY (Fig. 2).
However, the slight increase in EMSY protein level did not
repress HygR, since individual NeoR cell clones, grown in
parallel in G418- and Hyg-containing media, showed
similar plating efficiency. In addition, no apparent change












































Fig. 2 Short EMSY expression
in MCF-7 cell lines. PCR of
genomic DNA was performed
to demonstrate EMSY transgene
integration. The primer pair
employed amplifies only the
EMSY transgene. Its mRNA was
analyzed by qualitative RT-PCR
with the same primer pair. As a
control, a fragment from
endogenous full-length EMSY
was amplified in the same
reaction. 18S rRNA was
amplified as a control for
RT-PCR. Water or no reverse
transcriptase served as a
negative control, whereas
EMSY-expressing vector DNA
was used as a positive control.
EMSY proteins were assessed
by Western blotting. All the
different EMSY cell lines
examined are independent cell
clones
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Short EMSY represses spontaneous
RAD51-mediated HR
One can envisage at least four more mechanisms by which
short EMSY may affect spontaneous HR (i.e., without
exposure to exogenous DNA-damaging agents). First, it may
override PALB2 and thereby target BRCA2 for degradation
in a manner similar to PALB2 depletion (Xia et al. 2006).
Second, it may induce a BRCA2 conformational change that
may affect its ability to interact and/or co-localize with
RAD51, DSS1, or FANC-D2 at sites of DNA damage
(Gudmundsdottir and Ashworth 2006). These proteins
interact with the BRCA2 C-terminal domain, and deletion of
such a domain or disruption of its interacting proteins has
been shown to mimic BRCA2 deficiency, as revealed by
decreased efficiency of HR repair of I-SceI-induced DSBs
and hypersensitivity to PARP1 inhibitors and DSB-inducing
agents (Gudmundsdottir and Ashworth 2006; Moynahan and
Jasin 2010). In addition, deletion of the human BRCA2
C-terminal domain also increases the rate of spontaneous HR
(Abaji et al. 2005). Thus, in either scenario, EMSY-over-
expressing cell lines would exhibit all these phenotypes, as
BRCA2-deficient CAPAN-1 cells do (Abaji et al. 2005).
Third, short EMSY may directly repress the expression of
RAD51 gene or its transactivator PTEN, since cells depleted
of PTEN also undergo SC-type abnormalities similar to
RAD51-deficient cells (Shen et al. 2007), BRCA2-deficient
cells (Venkitaraman 2002) or short EMSY-expressing cells
(Raouf et al. 2005). Fourth, it may override PALB2 and RPA,
and thereby quench BRCA2 without affecting its stability. In
these two scenarios, short EMSY-expressing cells would be
expected to exhibit a hypo-recombination phenotype by
decreasing the rate of spontaneous HR.
To examine which scenario is more likely, single NeoR/
HygR, inverted-repeat MCF-7 cell clones and EMSY-
overexpressing derivatives were grown in parallel and
subjected to Puro selection. In contrast to direct repeats,
inverted repeats monitor exclusively RAD51-mediated HR:
gene conversion and crossover (inversion) events (Fig. 1).
EMSY-overexpressing MCF-7 cell lines displayed 4–16-
fold decreases in the rate of spontaneous HR, compared to
their parental cell lines containing the empty vector
(Table 1). In addition, no apparent difference in RAD51 or
BRCA2 gene expression was noted between parental and
derivative cell lines (Fig. 3). Since BRCA2 can bind only
20% of the cellular RAD51 pool (Marmorstein et al. 1998;
Yu et al. 2003), these findings indicate that short EMSY
repressed at least free RAD51 molecules.
Short EMSY heightens the rate of spontaneous SCRS
If short EMSY were to suppress spontaneous HR by
interfering solely with free RAD51 molecules, one would
expect no effect on SCRS, since the process is RAD51-
independent and yet down-regulated by both BRCA1 and
BRCA2 (Abaji et al. 2005; Cousineau et al. 2005). To
examine this, we tested direct-repeat cell lines that monitor
a mixture of HR and SCRS (Fig. 1). However, short EMSY
did not affect the rate of PuroR colony formation with
direct repeats, but significantly shifted gene conversion to
deletion events (Table 2), as revealed by PCR analysis of
the recombinants (Abaji et al. 2005). The increase in
deletion cannot be attributed to augmented crossover, since
Table 1 Effect of EMSY on spontaneous inverted-repeat HR
Cell lines Frequencya Ratiob Ratec Ratiod
iA7 2.05 ± 0.7 9 10-4 4.94 ± 0.7 9 10-5
iA7/EMSY-3B 3.25 ± 1.6 9 10-5 6.3 7.97 ± 1.0 9 10-6 6.2
iA7/EMSY-6 2.86 ± 1.4 9 10-5 7.2 7.24 ± 0.9 9 10-6 6.8
iA7/EMSY-9 5.61 ± 2.9 9 10-5 3.7 1.14 ± 0.4 9 10-5 4.3
iA7/EMSY-31 1.30 ± 0.5 9 10-5 15.8 3.33 ± 0.8 9 10-6 14.8
iA12 2.24 ± 1.0 9 10-3 3.25 ± 1.0 9 10-4
iA12/EMSY-13 2.76 ± 1.1 9 10-4 8.1 4.83 ± 1.2 9 10-5 6.7
iA12/EMSY-18 9.73 ± 2.3 9 10-5 23.0 2.03 ± 0.6 9 10-5 16.0
a Frequency is determined as the number of PuroR cell clones relative to the
total number of viable cells before selection
b Ratio (parent/EMSY-expressing derivative cell lines) indicates recombina-
tion fold decrease in EMSY-expressing cells relative to their parents
(p \ 0.0001)
c Rate represents the number of recombination events/locus/cell/generation
d Ratio (parent/EMSY-expressing derivative cell lines) (iA7, p = 0.0003;







Fig. 3 Effect of short EMSY on BRCA2 and RAD51 expression. RT-
PCR reveals no apparent effect of short EMSY on RAD51 or BRCA2
expression levels. 18S rRNA was amplified as a control for RT-PCR.
Water or no reverse transcriptase was a negative control. Western
blotting analysis indicates no apparent effect of short EMSY on
RAD51 protein level. Actin served as loading control
330 Mol Genet Genomics (2011) 285:325–340
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short EMSY represses such HR events at inverted repeats
(Table 1). In addition, neither BRCA2 nor BRCA1
represses crossover in favour of gene conversion as the
RAD51-interacting BLM or WRN helicase does with HR
intermediates containing crossed DNA strands: Holliday
junctions (HJs) (Abaji et al. 2005; Cousineau et al. 2005).
Collectively, these findings indicate that short EMSY not
only interferes with free RAD51 molecules and BRCA2/
RAD51 complexes, but also disrupts SCC/alignment.
Short EMSY represses BRCA2/RAD51-mediated HR
repair of DSBs
To examine this, direct-repeat MCF-7 cell lines and
EMSY-overexpressing derivatives were transiently co-
transfected in parallel with the pbactin/I-SceI vector, which
expresses I-SceI, and a GFP-expressing vector, employed
to evaluate transfection efficiency. No apparent difference
in cell viability was noted after transfection between the
parental cell line and EMSY-overexpressing derivatives
(data not included). When the Puro gene is cleaved at the
I-SceI site, HR repairs the DSB (Moynahan and Jasin
2010). I-SceI expression increases the frequency of PuroR
colony formation with all cell lines, whereas EMSY-
overexpressing derivatives consistently present threefold
fewer colonies than their parents do (Table 3).
HR repair of I-SceI-induced DSBs between direct repeats
occurs almost exclusively by gene conversion with few
deletion events attributed to SSA (Cousineau and Belmaaza
2007; Moynahan and Jasin 2010). SSA, which obligatorily
leads to deletion between direct repeats, cannot be moni-
tored with inverted repeats, since the processing of DSB
ends by BRCA1/MRN and ATM would generate identical
rather than complementary ssDNA ends that would anneal
(Fig. 1). Consistent with BRCA2/RAD51 complexes acting
downstream of BRCA1/MRN (Greenberg et al. 2006;
Zhang et al. 2009; Moynahan and Jasin 2010), the efficiency
of DSB repair by SSA decreases in BRCA1-deficient cells
and increases in RAD51- or BRCA2-deficient cells at the
expense of reduced gene conversion (Daboussi et al. 2002;
Abaji et al. 2005; Cousineau et al. 2005; Gudmundsdottir
and Ashworth 2006). To determine whether short EMSY
also affected DSB repair by SSA, we investigated the
structure of I-SceI-induced recombinants by PCR (Abaji
et al. 2005). Taking into consideration the threefold
decrease in the overall frequency of I-SceI-induced HR,
PCR analysis indicates that short EMSY lowers the effi-
ciency of gene-conversion repair by 3.7-fold and shifts DSB
repair from gene conversion to SSA, without affecting the
efficiency of the latter (Table 3).
Discussion
Briefly, our findings indicate that an increased level of the
EMSY N-terminal domain only partially mimics BRCA2
deficiency. Similar to BRCA2-deficient CAPAN-1 cells
(Abaji et al. 2005), EMSY-overexpressing MCF-7 cells also
Table 2 Effect of EMSY on spontaneous direct-repeat HR
Cell lines Frequency Ratio Rate Ratio GC (%) SCRS (%)
dA9 2.99 ± 0.8 9 10-6 6.56 ± 0.9 9 10-7 34/36 (94) 2/36 (6)
dA9/EMSY-7 2.30 ± 0.9 9 10-6 1.3 5.31 ± 0.8 9 10-7 1.2 12/14 (86) 2/14 (14)
dA9/EMSY-9 2.32 ± 0.7 9 10-6 1.3 5.35 ± 0.9 9 10-7 1.2 9/11 (82) 2/11 (18)
dA9/EMSY-16 2.87 ± 0.7 9 10-6 1.0 5.72 ± 0.7 9 10-7 1.1 25/33 (76) 8/33 (24)
dA9/EMSY-19 2.55 ± 1.0 9 10-6 1.2 5.84 ± 0.7 9 10-7 1.1 56/92 (61) 36/92 (39)
dA9/EMSY-20 3.17 ± 1.4 9 10-6 0.9 6.84 ± 1.0 9 10-7 1.0 23/30 (77) 7/30 (23)
Frequencies, rates and ratios were determined as described in Table 1
GC gene conversion
The apparent absence of EMSY effect on the frequency (p = 0.93) and rate (p = 0.43) of spontaneous PuroR colony formation appears to be due
to a decrease in RAD51-mediated GC events compensated by an increase in RAD51-independent SCRS events (p = 0.004)
Table 3 Effect of EMSY on I-SceI-induced HR
Cell lines Frequencya Ratiob GC (%)c SSA (%)
dA9 217.63 ± 67.6 68/74 (92) 6/74 (8)
dA9/EMSY-7 81.32 ± 40.3 2.7 53/68 (78) 15/68 (22)
dA9/EMSY-9 75.59 ± 38.5 2.9 66/90 (73) 24/90 (27)
dA9/EMSY-16 70.21 ± 21.3 3.1 52/66 (79) 14/66 (21)
dA9/EMSY-19 71.64 ± 33.0 3.0 55/78 (71) 23/78 (29)
dA9/EMSY-20 82.45 ± 37.2 2.6 47/58 (81) 11/58 (19)
GC gene conversion, SSA single-strand annealing
a Frequency fold induction represents the mean of at least three
independent experiments for each cell line (p = 0.0064)
b Ratio indicates recombination fold decrease in EMSY-expressing
cells relative to their parents
c EMSY shifts the proportion of GC events to SSA (p = 0.029); the
absolute value of SSA events remained unchanged but their propor-
tion increased in comparison to the decreased number of GC events
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exhibit an increased rate of SCRS and a deficit in HR repair of
I-SceI-induced DSBs. However, unlike CAPAN-1 cells that
present an increased rate of spontaneous HR and heightened
efficiency of DSB repair by SSA (Abaji et al. 2005), EMSY-
overexpressing MCF-7 cells rather display a decreased rate of
the former and normal efficiency of the latter.
The differential effect of short EMSY on these processes,
together with the lack of influence on expression of the
reporter genes Hyg and Puro at three distinct loci and
endogenous RAD51, BRCA2 and EMSY, seems to argue
against EMSY as a general chromatin-assembly factor/
transcription repressor. The lack of effect on gene expres-
sion could not be attributed to the slight elevation of EMSY
level in MCF-7 cell lines, as a higher level of a similar
truncated form of EMSY in a telomerase-immortalized
human breast epithelial cell line also does not affect
BRCA2, BRCA1, p53 or p21 expression (Raouf et al. 2005).
In addition, it also does not much affect the stability of
BRCA2 protein or its ability to interact and/or co-localize
with RAD51, since this would confer hyper-recombination
as BRCA2 deficiency does (Abaji et al. 2005). Rather, short
EMSY bestows hypo-recombination by decreasing the rate
of spontaneous HR, presumably by enhancing the repres-
sive effect of BRCA2 on RAD51 (Abaji et al. 2005).
Both the promotion of RAD51 activity by BRCA2 in
response to I-SceI-induced DSBs and its repression in the
absence of such lethal damage were thought to be
orchestrated by BRCA1, ATR and ATM (Abaji et al. 2005;
Cousineau et al. 2005). Consistent with this view are the
findings that, in undamaged human cells, the BRCA2
C-terminal RAD51-binding motif ser3291 encoded by
exon27 (BRCA2ex27) is phosphorylated by CDK1, a post-
translational modification that blocks its interaction with
RAD51 (Thorslund and West 2007). However, after the
induction of DSBs that inactivate CDK1, BRCA2ex27
becomes de-phosphorylated, and its ability to both bind
RAD51 and carry out HR repair of such lethal damage is
restored (Thorslund and West 2007). RAD51 is functional
as oligomers (1 oligomer contains 6 or 7 RAD51 mono-
mers) that coat 30-ssDNA and form a nucleoprotein fila-
ment that undertakes the DNA strand-exchange reaction by
invading an intact homologous DNA (dsDNA) to prime
new DNA synthesis and thus repair the damage (Thorslund
and West 2007). Whereas the eight BRC repeats encoded
by exon 11 (BRCA2ex11) can bind both RAD51 monomers
and oligomers, BRCA2ex27, which is unrelated to BRC
repeats, exclusively binds RAD51 oligomers or RAD51
filament (Thorslund and West 2007). Since BRCA2 can
bind only 20% of the cellular RAD51 pool (Marmorstein
et al. 1998; Yu et al. 2003), one way by which short EMSY
could repress both spontaneous HR and HR repair of DSBs
is to both disrupt RAD51 oligomers into monomers and
maintain BRCA2ex27 phosphorylation.
EMSY-overexpressing MCF-7 cells exhibit approxi-
mately a fourfold decrease in the efficiency of HR repair of
I-SceI-induced DSBs similar to BRCA1- or BRCA2-defi-
cient tumor cells (Abaji et al. 2005; Cousineau et al. 2005),
or hypoxic human cells, since hypoxia also decreases
the synthesis of HR proteins to offset chemo- and radio-
resistances (Chan et al. 2008). Consistently, a similar
decrease has also been reported with cells repressed or
disrupted in BARD1 (Westermark et al. 2003); MRN (Yang
et al. 2006); BRIP1 (BRCA1-interacting protein, also
known as the helicase BACH1) (Litman et al. 2005); CtIP
that links BRCA1 to MRN (Chen et al. 2008); ATM
(Golding et al. 2004); ATR (Wang et al. 2004); CHK2
(Zhang et al. 2004); CHK1 (Sorensen et al. 2005); PALB2
(Xia et al. 2006); RPA (Sleeth et al. 2007); or RAD51
(Daboussi et al. 2002). Since short EMSY neither represses
the expression of HR reporter genes nor affects SSA effi-
ciency, the fourfold decrease in HR repair of I-SceI-induced
DSBs cannot be ascribed to chromatin assembly diminish-
ing DNA accessibility to transcription factors and restric-
tion enzymes (Villemure et al. 2001). Rather, it could be
due to either reduced efficiency of RAD51-mediated DNA
strand-exchange/invasion or I-SceI-induced cell death
(apoptosis) or permanent cell-cycle arrest (senescence), in
which case the essential role of HR in cell survival would be
at least checkpoint rather than DSB repair per se. Consistent
with this view, (a) all these HR mutant cells are hypersen-
sitive to DSB-inducing agents that activate p53-dependent
or independent apoptosis/senescence; (b) after p53 disrup-
tion or repression, the efficiency of HR repair of I-SceI-
induced DSBs increases by up to 20-fold, whereas the rate
of spontaneous HR remains unchanged in the absence of
such lethal damage (Akyuz et al. 2002; Lemelin et al.
2005); and (c) similar to BRCA1, both BRCA2 and RAD51
bind p53, and BRCA2/RAD51 complex represses the
expression of p53-responsive genes in transient assays
(Marmorstein et al. 1998). In such assays, DNA transfection
per se can activate DDR, specifically the ATR/ATM path-
way (Igoucheva et al. 2006), and DDR activation can
repress both p53-dependent and independent gene expres-
sion (Zhou et al. 2007), and p53 can repress not only cel-
lular genes but also all viral promoters that drive the
expression of HR/transcription-reporter genes (Lemelin
et al. 2005). Thus, since the I-SceI assay system does not
discriminate between checkpoint/repair and apoptosis/
senescence, short EMSY may affect all DDR aspects.
However, short EMSY does not seem to interfere with
the localization of activated ATM, the processing of DSB
ends into ssDNA by BRCA1/MRN or the stability of
ssDNA ends. If it were to negatively affect any of these
processes, one would have expected a similar decrease in
the efficiency of DSB repair by SSA, which also requires
all these HR proteins, except BRCA2/RAD51 complex that
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would shift DSB repair from SSA to gene conversion
(Abaji et al. 2005; Gudmundsdottir and Ashworth 2006;
Moynahan and Jasin 2010). Rather, short EMSY shifted
DSB repair from gene conversion to SSA without affecting
the efficiency of the latter. Thus, it seems that short EMSY
interferes with free RAD51 molecules and the loading of
RAD51 oligomers by BRCA2ex27 at least at DSBs
(Thorslund and West 2007), without affecting the ability of
BRCA2/RAD51 to bind/stabilize ssDNA and promote
SSA.
The SSA-promoting activity of BRCA2 has been
appreciated with human full-length BRCA2 in CAPAN-1
cells (Abaji et al. 2005), and with its mini-homologs Brh2
in the smut, yeast-like fungus Ustilago maydis and
CeBRC2 in C. elegans (Petalcorin et al. 2006; Mazloum
et al. 2007). However, evidence indicates that in mammals,
the SSA-promoting activity of BRCA2 may be overshad-
owed in the context of at least RPA/BRCA2/RAD51
complex and may become apparent only after the loss of
either component of this complex. (a) In RAD51-disrupted
cells that exhibit increased efficiency of SSA at I-SceI-
induced DSBs (Daboussi et al. 2002), RPA/BRCA2 could
still bind/stabilize ssDNA ends and promote SSA, given
that similar to RPA and RAD51, BRCA2 also binds
ssDNA, its C-terminal domain contains both ssDNA
and dsDNA-binding motifs (Thorslund and West 2007).
(b) Likewise, in BRCA2-disrupted cells that also display
heightened efficiency of SSA at I-SceI-induced DSBs
(Abaji et al. 2005; Gudmundsdottir and Ashworth 2006),
RPA/RAD51 could still bind ssDNA ends and promote
SSA. However, in this case, the ability of RAD51 alone to
bind and displace RPA from ssDNA and form RAD51
filament to carry out DNA strand-exchange/invasion, as it
does in vitro (Stauffer and Chazin 2004) and in CAPAN-1
cells causing hyper-recombination (Abaji et al. 2005), is
crippled by I-SceI-induced DSBs (Abaji et al. 2005). In
response to DSBs, ATM and its BRCA1-interacting tyro-
sine kinase c-ABL, another downstream target of DNA-
PK, as well as ATR proximal kinase CHK1, each phos-
phorylates RAD51 (Daboussi et al. 2002; Shiloh 2003;
Sorensen et al. 2005).
It has been shown that RAD51 phosphorylation cripples
the ability of RAD51 to both bind ssDNA and undertake
DNA strand-exchange/invasion in vitro and HR repair of
I-SceI-induced chromosomal DSBs, presumably by dis-
rupting RAD51 oligomers into monomers and preventing
RAD51 oligomerization (Yuan et al. 1998; Daboussi et al.
2002; Conilleau et al. 2004). Thus, in response to DSBs,
RAD51 phosphorylation would affect not only its function
but also that of BRCA2, since de-phosphorylated
BRCA2ex27 exclusively binds RAD51 oligomer but not
RAD51 monomers (Thorslund and West 2007), raising the
question: how does BRCA2/RAD51 complex conduct HR
repair of DSBs? Since none of the models proposed for HR
in general or for BRCA1/2 function in particular considers
such a conundrum, we propose that BRCA2 may have the
ability to protect its RAD51 monomers bound by the BRC
repeats (exon 11) against phosphorylation (Abaji et al.
2005) (Fig. 4a).
(c) In the absence of RPA, BRCA2/RAD51 could still
bind/stabilize ssDNA and promote SSA. Consistently, in in
vitro assays, the BRCA2 C-terminal domain, Brh2 or
CeBRC2 can displace RPA from ssDNA, load RAD51
oligomer onto the dsDNA–ssDNA junction that mimics
one processed DSB end, and promote SSA between
RAD51 filament and its complementary ssDNA, provided
as linear, circular or embedded in synthetic D-loops
(Petalcorin et al. 2006; Mazloum et al. 2007; Thorslund
and West 2007; Fig. 4b).
Since short EMSY does not seem to negatively affect the
SSA-promoting activity of BRCA2/RAD51, it must have
then interfered at least with the loading of RAD51 oligomer
by BRCA2 (Thorslund and West 2007). However, the
loading of RAD51 oligomer by BRCA2 at DSBs can-
not occur before recruitment/activation of ATR, since
BRCA2ex27 would be still phosphorylated by CDK1. Then,
the supply of RAD51 oligomers for RAD51 filament for-
mation could originate afterwards from the BRC repeats
of RPA/BRCA2/RAD51, EMSY/BRCA2/RAD51 and
PALB2/BRCA2/RAD51, with each complex providing
eight non-phosphorylated RAD51 monomers and, thus, a
total of three to four RAD51 oligomers. This may be suffi-
cient for HR repair, given previous demonstrations that only
one DSB end can invade the undamaged template and prime
new DNA synthesis, whereas the other DSB end can capture
the displaced, newly synthesized DNA strand through SSA
(Fig. 4b) or NHEJ under certain circumstances, culminating
in deletion, insertion, or amplification events (Belmaaza and
Chartrand 1994; Villemure et al. 1997, 2003). Thus, by
overriding at least RPA, short EMSY could block the
recruitment/activation of ATR, not only at stalled forks—
increasing the likelihood of their collapse into DSBs (Raouf
et al. 2005) as BRCA2 deficiency does (Lomonosov et al.
2003)—but also at such DSBs without affecting the locali-
zation of ATM or the processing of DSBs into ssDNA ends
by BRCA1/MRN. This would decrease SCC/alignment,
induce RAD51 phosphorylation, and maintain BRCA2ex27
phosphorylation, thereby increasing SCRS and repressing
both spontaneous HR and HR repair of DSBs without
affecting SSA, as found to be the case.
That EMSY/BRCA2, RPA/BRCA2 and PALB2/
BRCA2 complexes have independently been fractionated
from undamaged human cells indicates that, similar to
PALB2, EMSY and RPA are also partners and stabilizers
of BRCA2 (Hughes-Davies et al. 2003; Wong et al. 2003;
Xia et al. 2006). However, regardless of their proportions
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in cells, increased EMSY level would be expected to shift
protein concentration equilibrium towards EMSY/BRCA2,
overriding PALB2 and RPA by quenching BRCA2 without
affecting its overall stability. As it still interacts with HP1b
and BS69, short EMSY might also override full-length
EMSY. However, notwithstanding the exact role of full-
length EMSY, the effects of short EMSY reported here
provide evidence that, in addition to chromatin and
transcription regulation, BRCA2ex3 may also be directly
involved in the development of DDR in at least replication/
checkpoint and recombination/repair.
Such a heretofore unappreciated function of BRCA2
can be best examined in phenotypes of BRCA2 knockout
(KO) mice. Whereas BRCA2 null, BRCA2Dex1-5 and
BRCA2Dex11 KO mice all die at an early embryonic stage in









































Fig. 4 A model for the BRCA2/RAD51 pathway in response to
DSBs. Not all proteins and protein–protein interactions are shown
and the outlines are for illustration only. a After their recruitment
by BRCA1/MRN, BRCA2/RAD51 complexes act upstream and
downstream of ATR (see text for details). b After disruption of
nucleosomes and transformation of DSB ends into ssDNA by
BRCA1/MRN and ATM (1), RPA/BRCA2/RAD51 recruits ATR
(2) to enhance SCC/alignment before the formation/stabilization of
D-loop at which the 30-ssDNA end primes new DNA synthesis (3).
ATR recruitment/activation could also occur during or after strand
invasion and D-loop formation/stabilization, since transformation of
DSB ends into 30-ssDNA could be performed by the unwinding
activity of MRN rather than its exonuclease activity that normally
yields 50-ssDNA ends. In this case, unwinding, strand invasion and
D-loop formation/stabilization could occur simultaneously after the
search for homology, alignment/pairing between DSB ends and the
intact homologous dsDNA partner. In either case, the resulting
intermediate can either disassemble, the newly synthesized strand can
be displaced by unwinding to anneal with the non-invading 30-ssDNA
end to elicit non-crossover gene conversion only, or be processed to
yield gene conversion with or without crossover (4). Short EMSY
interferes with ATR recruitment/activation by overriding RPA (5),
without affecting the ability of BRCA2/RAD51 to bind ssDNA and
perform SSA (6). At D-loops, such as at gene promoters and
replication origins, free RAD51 oligomers could also compete with
RNA and DNA polymerases for ssDNA and thereby block initiation
of transcription, replication and repair until activation/recruitment of
PIKKs that would disrupt RAD51 oligomers into monomers. The
loading of RAD51 oligomers by BRCA2ex27 on ssDNA may also act
similarly until disruption of RAD51 filament by post-translational
modifications (i.e., phosphorylation, ubiquitylation, sumoylation) that
would allow transcription, replication and repair to proceed and
thereby resume cell-cycle arrest. In this case, transcription and
replication factors could act as cellular GPS (guiding position system)
elements, recruiting checkpoint proteins to specific sites. Such
BRCA2/RAD51 transcription/replication-checkpoint function could
explain why checkpoint-deficient cells exhibit radio-resistant DNA
synthesis, a characteristic feature of CIN syndromes, including
BRCA-deficiency (see text). Thus, whereas RAD51 oligomer can act
as a transcription/replication/repair repressor upstream of PIKKs,
BRCA2/RAD51 complex can behave as both an activator and a
repressor upstream and downstream of PIKKs, respectively
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KO mice are viable and develop normally (Donoho et al.
2003; Evers and Jonkers 2006; Friedberg and Meira 2006),
indicating that whereas the function of at least BRCA2ex3
and BRCA2ex11 in replication/checkpoint is essential, that
of BRCA2ex27 in RAD51-mediated HR repair of DSBs and
resistance to DSB-induced lethality (Thorslund and West
2007; Moynahan and Jasin 2010) is dispensable for cell
survival, proliferation and differentiation. The embryonic
lethality of BRCA2 KO mice has been associated with
chromosomal breakage and activation of p53, suggesting
that: (a) such lethal damage does not arise accidentally in
BRCA2Dex27 KO mice or normal proliferating/differentiat-
ing cells; and (b) the essential role of BRCA2 in replica-
tion/checkpoint is at least to prevent fork collapse into fatal
injury rather than promote RAD51-mediated HR repair of
collapsed forks.
Consistently, in response to fork stalling, bacteria, bud-
ding or fission yeast do not undergo fork collapse; only
replication/checkpoint mutants do, through the activities of
HR enzymes (Branzei and Foiani 2005). Such organisms do
not possess BRCA homologs and yet they carry out DSB
repair almost exclusively by HR. In contrast, in organisms
that possess BRCA homologs, NHEJ is the predominant
DSB repair pathway, whether at collapsed forks or IR/
enzyme-induced DSBs. Therefore, in such evolved organ-
isms, one would expect NHEJ and SSA to rescue HR
mutants from DSB-induced lethality. In contrast, KO of HR
genes, such as RPA, RAD51, BRCA1, BARD1, MRE11,
RAD50, NBS1, ATR, CHK1, RAD51B, RAD51D, XRCC2,
TOPII, and BLM, in mice makes them all undergo chro-
mosomal breakage and succumb to death in a manner
similar to BRCA2 KO mice (Friedberg and Meira 2006).
Thus, in addition to their well-established role in HR repair
of DSBs, RAD51 and its paralogs RAD51B, RAD51D and
XRCCs are also essential for checkpoint/fork stability.
Consistent with this aspect, not all RAD proteins required
for HR repair of DSBs are essential for survival; RAD52,
RAD54 and RAD51C KO mice were all found to be viable
(Friedberg and Meira 2006).
In addition, ATM, master of the response to DSBs
including their repair by HR, NHEJ and SSA, is also dis-
pensable for survival; KO mice remain viable, except that
they exhibit hyper-sensitivity to IR, gonadotrophy, infer-
tility, immunodeficiency and thymic lymphoma, since in
germ-line cells and lymphocytes, DSBs rather arise in a
programmed manner to initiate meiotic HR, ensuring
‘‘gene shuffling’’ and the orderly segregation of homolo-
gous chromosomes and thus the formation of healthy
gametes, and V(D)J recombination (NHEJ) for immune
system development, protecting against infectious diseases
and cancer (Friedberg and Meira 2006). In the absence of
ATM, such ‘heavenly’ breaks could trigger apoptosis/
senescence and act as anti-cancer barriers in ‘specialized’
tissues at the expense of their atrophy. Consistently, ATM/
RAG1 and ATM/RAG2 double KO (DKO) mice that no
longer undergo programmed DSBs and V(D)J recombina-
tion also develop CIN and lymphoma (Petiniot et al. 2002).
Moreover, other ATM downstream targets that play a role
in HR repair of DSBs are also dispensable for survival;
CHK2 and H2AX KO mice are as viable as ATM/CHK2
and ATM/H2AX DKO mice (Friedberg and Meira 2006).
Furthermore, NHEJ key components, including DNA-PK,
another master of DSBs, Ku70, Ku80, Ku86 and Artemis,
except ligase IV, are also dispensable for survival; KO
mice remain viable (Friedberg and Meira 2006); and last
but not least, genes of mutation-avoidance systems, such as
base-excision repair/single-strand break repair (BER/
SSBR) of oxidative damage (XRCC1, APEX, LIG1, POLb,
FEN, PARP1/PARP2), nucleotide-excision repair (NER)
and transcription-coupled NER of DNA adducts (XPD,
XAB), or translesion DNA synthesis (TLS) (REV3), which
are not necessary for DSB repair, all appear to be essential
for survival (Friedberg and Meira 2006). Collectively,
these findings indicate that (a) checkpoint/fork stability
requires the participation of components of all DNA-
damage repair mechanisms—HR, SSA, NHEJ, BER/
SSBR, NER and TLS—rather than DNA damage/repair per
se; (b) the same machinery that responds to programmed
DSBs also acts to suppress accidental breakage in both
specialized and normal tissues; and (c) DSB has been
conceived as a fundamental requirement of life, evolution
and death, acting as a ‘longevity clock’ and ‘quality con-
trol’, eliminating aberrant proliferating/differentiating cells
(cancer) and embryos (abortion).
In such replication/checkpoint mutants, the collapse of
stalled forks into lethal DSBs has been associated with
cleavage of HR intermediates (HJs) resembling a chicken-
foot structure that forms as a consequence of ‘‘replication-
fork reversal’’ (RFR) or ‘‘run-off’’ of specialized SC junc-
tions resembling hemicatenanes (pseudo-double HJs)
(Branzei and Foiani 2005; Fig. 5). In yeast, pseudo-double
HJs have been shown to form during the early S phase, after
origin firing, and to migrate, chasing the forks and pre-
sumably assisting SCC/alignment until anaphase whereas in
human cells, such SC bridges have been reported to form at
fragile sites, after replication stress, and at anaphase before
their resolution by BLM/TOPIIIa and TOPII and SC seg-
regation as two intact chromosomes (Branzei and Foiani
2005, 2007; Chan et al. 2007, 2009). In yeast, pseudo-
double HJs are thought to form at stalled forks by strand
invasion and D-loop formation (template switch) as an
error-free DNA-damage bypass mechanism compared to
TLS polymerases, which often replicate across lesions in an
error-prone manner (Branzei and Foiani 2007). Since
BRCA2Dex27 cannot carry out RAD51-mediated strand
invasion (Thorslund and West 2007), ‘hemicatenation’
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(HR) in mammals may result instead from BRCA2/RAD51-
mediated strand switching: twisting/melting dsDNA into
ssDNA and, thus, displacement of both lagging and leading
strands and their subsequent annealing into one harmless
DSB end, flipping out the chicken foot, recruiting/activating
ATR, ATM and DNA-PK to terminate HR within an intact
chromosome (Fig. 5).
In support of this, (a) its mini-homologs Brh2 and
CeBRC2 that each contains only one RAD51-binding BRC
motif and one ssDNA-binding domain possess the ability to
twist dsDNA into both D-loops and ssDNA and carry out
SSA (Petalcorin et al. 2006; Mazloum et al. 2007; Fig. 4b).
BRCA2Dex27 would be expected to conduct such reactions
with higher efficiency, as it still possesses eight dsDNA- and
ssDNA-binding motifs through its interaction with RAD51,
given that RAD51 binds to ssDNA (50 or 30) and dsDNA with
comparable affinities (Forget and Kowalczykowski 2010).
In addition, the binding of RAD51 oligomers to the
homologous dsDNA partner inhibits DNA strand-exchange/
invasion in vitro and can be modulated by BRC repeats
(Forget and Kowalczykowski 2010). In this case, BRCA2/
RAD51 complexes together with free RAD51 oligomers
may also stabilize replication forks by holding SCs aligned,
acting as bridges until activation of replication/checkpoint
that would disrupt RAD51 oligomers into monomers and
recruit bona fide cohesins (Fig. 5). (b) Mouse embryonic
stem (ES) cells expressing BRCA2Dex27 exhibit heightened
efficiency of SSA at I-SceI-induced DSBs and hyper-sen-
sitivity to IR, but maintain both G1/S and G2/M checkpoints
and resistance to UV radiation as wt ES cells (Morimatsu
et al. 1998; Jasin 2002; Gudmundsdottir and Ashworth
2006), indicating that BRCA2Dex27 is still efficient in
recruiting/activating at least ATR and DNA-damage repair
by error-free TLS, NER, BER/SSBR, or mismatch repair
(MMR) (Branzei and Foiani 2008). MMR key proteins are
also components of BASC (Wang et al. 2000), and although
dispensable for survival (Friedberg and Meira 2006), they
have also been implicated in DDR and the processing of HR
intermediates containing HJs or branched DNA in collabo-
ration with NER proteins (Villemure et al. 2003). (c) NER,
transcription-coupled NER and PCNA-dependent pathways






















Fig. 5 A model for the BRCA2/RAD51 pathway in the response to
stalled forks. After their recruitment by BRCA1/MRN, BRCA2/
RAD51 complexes may act in concert to (i) disassemble chromatin
(A); (ii) maintain SCC/alignment (B); (iii) effectuate strand-switching
and thereby recruit/activate ATR to enhance SCC/alignment (C); (iv)
provide one DSB end, and thereby activate ATM and DNA-PK (D);
and (v) twist the DSB end after its processing at least by error-free
TLS polymerases into leading and lagging strands that would anneal
back with the original templates, and thereby yield a hemicatenane
(E). If needed, the harmless DSB end (D and F) may engage in HR,
NHEJ or SSA between neighbouring stalled forks during termination
of the replication (S) phase (not shown). By interfering with ATR
recruitment/activation, short EMSY could induce RFR (RAD51-
independent HR) and chicken-foot formation (F). HJ-resolving
enzymes against crossover, such as BLM and WRN, may prevent
fork collapse (G) by competing with HJ-nicking enzymes (red
arrows) at the expense of CIN. Unlike hyper-recombination, BRCA2/
RAD51-mediated strand switching at either stalled forks (hemicate-
nation/RFR) or DSBs does not require RAD51-filament formation, in
which case the fourfold decrease in HR repair of I-SceI-induced DSBs
by short EMSY could be attributed to apoptosis/senescence rather
than decreased efficiency of strand switching. Consistently, meiotic
HR does not require the loading of RAD51 oligomers by BRCA2 at
programmed DSBs, since BRCA2Dex27 KO mice are as fertile as wild-
type animals, except that they exhibit hypersensitivity to IR,
senescence and reduced life span. Thus, whereas BRCA2/RAD51-
mediated strand switching ensures survival, maintains chromosomal
stability and acts as an anti-cancer barrier, SCRS and RAD51-
mediated strand exchange/invasion can compete with RFR for ssDNA
and thereby decrease the likelihood of forks collapse at the expense of
CIN and human diseases. Only abnormally proliferating cells crippled
in an essential gene are prone to gene mutation/reversion and fork
collapse
b
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and ATR (Le Page et al. 2000; Bogliolo et al. 2000;
Daboussi et al. 2002; Aboussekhra and Al-Sharif 2005;
Auclair et al. 2008). (d) As the localization of activated
ATM and BRCA2/RAD51 complexes by BRCA1/MRN is
needed for ATR activation in response to DSBs, that of ATR
also seems to be required for ATM and DNA-PK activation
in response to stalled forks (Stiff et al. 2006; Yajima et al.
2006). (e) BRCA1 and ATR have been shown to enforce
TOPII-mediated decatenation G2 checkpoint (Deming et al.
2001). In normal proliferating cells, all replication forks
would stall at termination of the S phase by catenanes,
positive DNA supercoils that develop under torsional stress
between advancing/colliding forks, acting as topological
barriers, activating TOPII-mediated decatenation of SCs to
allow completion of the S phase, chromosome condensation
and segregation during the G2 and M phases (Deming et al.
2001; Branzei and Foiani 2008). Thus, with its HAT on
doing the twist and changing partners at DNA, BRCA2Dex27
still has the ability to provide a finger to any stalled fork, and
thereby act upstream and downstream of PIKKs, orches-
trating at least S/G2/M-transition checkpoints and mutation-
avoidance systems as full-length BRCA2, ensuring the
accuracy rather than efficiency of such DNA transactions
that can be carried out in vitro and by organisms that do not
possess BRCA homologs.
In addition, unlike humans, BRCA2Dex27 KO mice or
mice heterozygous for BRCA2-truncating mutations are not
spontaneously more cancer-prone than wt animals (Donoho
et al. 2003; Evers and Jonkers 2006). Moreover, unlike
BRCA2-deficient human cells (Abaji et al. 2005), mouse
cells expressing BRCA2Dex27 have not been reported to
undergo hyper-recombination or SCRS (Gudmundsdottir
and Ashworth 2006; Moynahan and Jasin 2010). These two
‘mutator’ phenotypes and cancer predisposition highlight
the importance of both replication/checkpoint in chromo-
somal stability and the difference between human and
mouse BRCA2. Whereas human BRCA2 contains one
nuclear localization signal (NLS) at the C-terminal domain,
mouse BRCA2 possesses an additional NLS at the
N-terminal domain (Jasin 2002). The majority of inherited,
cancer-eliciting BRCA2 mutations encode truncated pro-
teins as in CAPAN-1 cells, where BRCA2 is truncated at
exon 11, weakly expressed, and exclusively localized in the
cytoplasm, allowing both hyper-recombination and SCRS to
take place (Abaji et al. 2005). Conversely, truncated mouse
BRCA2Dex27 is expressed normally and localizes exclu-
sively in the nucleus (Jasin 2002).
Hyper-recombination and its hallmarks are characteris-
tic features of not only BRCA-deficient and BRCA-haplo-
insufficient tumor cells, but also normal breast epithelial
cells and lymphocytes from healthy carriers of BRCA
mutations, indicating that a ‘single hit’ in a chromosomal
stability gene is sufficient to deregulate HR and induce CIN
and the emergence of pre-cancerous lesions (Cousineau
and Belmaaza 2007). Although somatic BRCA mutations
are scarce in sporadic breast cancer, representing less than
1%, the remaining cases are either BRCA1- or BRCA2-
haploinsufficient due to loss (deletion/aneuploidy) or epi-
genetic silencing of wt BRCA alleles (Welcsh and King
2001), and all exhibit amplification of oncogenes most
notably EMSY, MYC, E2F-1, CyclinD1, or AKT, or loss of
tumor-suppressor genes, such as PTEN, p53, or RB
(Kenemans et al. 2004). Similar to EMSY, amplification/
overexpression of other oncogenes, such as MYC or E2F-1,
has also been shown to induce fork stalling and CIN as well
as fork collapse into DSBs, activating ATM and not ATR,
triggering apoptosis/senescence, acting as an anti-cancer
barrier (Hong et al. 2006; Halazonetis et al. 2008). Thus,
oncogenes can behave as tumor suppressors. Similarly,
aneuploidy also acts both oncogenically and as a tumor
suppressor (Weaver et al. 2007).
Hyper-recombination and its hallmarks are also charac-
teristic features of PARP1- and ATM-deficient cells or KO
mice (Claybon et al. 2010) and cells disrupted in DNA-PK
(Allen et al. 2002) or MMR proteins (Villemure et al. 2003),
or cells expressing p53 mutant proteins (Daboussi et al.
2002; Akyuz et al. 2002; Lemelin et al. 2005) or derived
from patients with CIN syndromes, such as ataxia telangi-
ectasia, Bloom’s syndrome, Werner’s syndrome, and Fan-
coni’s anemia, associated with mutations in ATM, BLM,
WRN, and several FANC genes, respectively (Meyn 1997).
Consistently, the most notable of FANC genes include
FANC-D1 (BRCA2), FANC-D2, FANC-J (BRIP1, BACH1),
and FANC-N (PALB2) (Walsh and King 2007). In addition,
similar to BRCA1 and BRCA2, the inheritance of a mutated
copy of ATM, PALB2, BRIP1, p53 or CHK2 (mutated in
Li-Fraumeni syndrome), MRE11 (mutated in ataxia telan-
giectasia-like disease), NBS1 (mutated in Nijmegen break-
age syndrome), or PTEN (mutated in Cowden disease) also
confers a high lifetime risk of developing breast cancer
(Walsh and King 2007). Cancer predisposition aside,
patients with these syndromes also suffer from several other
illnesses, such as neurological and cardiovascular diseases,
diabetes, immunodeficiency, anemia, infertility, or pre-
mature aging as patients with Xeroderma pigmentosum,
Cockyane syndrome, Trichothiodystrophy and Rothmund-
Thompson syndrome, associated with mutations in compo-
nents of NER, transcription-coupled NER, and RecQ-like
DNA helicases such as BLM and WRN (Shiloh 2003;
Vogelstein and Kinzler 2004; Branzei and Foiani 2008).
In conclusion, we briefly wielded the ‘triple-edged’ sword
of HR: life, death and human diseases. That BRCA1 and
BRCA2 act upstream of PIKKs as the masters of chromo-
somal stability may also explain: (a) why among all the
inherited, breast cancer-eliciting gene mutations identified to
date, BRCA1 and BRCA2 represent the majority of cases,
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whereas ATM, CHK2, p53, MRE11, RAD50, PALB2, BRIP1
(BACH1) and PTEN each accounts for approximately 1% of
the remaining cases (Walsh and King 2007); (b) why in
sporadic breast cancer, the majority if not all cases are either
BRCA1- or BRCA2-haploinsufficient (Welcsh and King
2001); and (c) why breast cancer exhibits decreased or
increased levels of almost exclusively those proteins that
interact with BRCA1 and BRCA2. This indicates that
(a) cancer may be a gene-dosage disease, in which tumor-
suppressor genes and oncogenes are two facets of the same
process with dosage amount acting both as a cancer promoter
and an anti-cancer barrier through fork stalling and collapse,
respectively; and (b) tissue specificity of the tumor-sup-
pressive or -promoting property of all these housekeeping
chromosomal stability genes may be determined by tissue-
specific DNA-damaging agents, such as estrogens, anti-
estrogens and phytoestrogens in breast cancer. The anti-
cancer facet of such compounds could be enhanced if
employed as tissue-specific carriers of potent DSB-inducing
drugs.
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